Home・Listă Acțiuni・Ardelyx Inc

Ardelyx Inc

Închisă

SectorSănătate

5.01 1.01

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

4.88

Maxim

5.01

Indicatori cheie
By Trading Economics
Venit	-37M -38M
Vânzări	-31M 94M
EPS	-0.15
Marjă de profit	-39.805
Angajați	489
EBITDA	-40M -30M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+236.77% upside

Dividende
By Acuity
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-219M 1.2B
Deschiderea anterioară	4
Închiderea anterioară	5.01

Sentimentul știrilor

By Acuity

50%

151 / 340 Clasament în Healthcare

Ardelyx Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 aug. 2026, 19:16 UTC

Ardelyx Inc. shares are trading roughly flat with no specific news identified. The stock remains below its 20-day moving average.

31 iul. 2026, 19:16 UTC

Ardelyx Inc. shares are lower, reflecting broader market trends amid rising yields and inflationary pressures, particularly after a notable increase in crude oil prices.

30 iul. 2026, 23:51 UTC

Ardelyx Inc. shares are lower in after-market trading, remaining below their 20-day moving average amid broader market weakness.

22 iul. 2026, 19:31 UTC

Ardelyx Inc shares are higher in Wednesday's session, continuing a modest rise since Tuesday's close. The stock remains below its 20-day moving average.

20 iul. 2026, 19:02 UTC

Ardelyx shares are lower today, reflecting broader weakness in the biotechnology sector. The stock has declined since Friday's close with no specific news identified.

Comparație

Modificare preț

Ardelyx Inc Așteptări

Obiectiv de preț

By TipRanks

236.77% sus

Prognoză pe 12 luni

Medie 16.67 USD 236.77%

Maxim 19 USD

Minim 15 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArdelyx Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

3 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 3 analiști care au acordat evaluări ale acțiunilor Ardelyx Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

151 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.